Wilson Sonsini Goodrich & Rosati and O’Melveny advised Belite Bio on the deal. Belite Bio, Inc., a clinical-stage biopharmaceutical drug development company, announced the pricing of...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised 1859, Inc. on the deal. 1859, Inc., a platform company combining artificial intelligence and empirical pico-scale screening data at scale...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Arcaea on the deal. Arcaea, a company launched on the Ginkgo Bioworks platform, announced its $78 million Series A to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Capsigen Inc. on the deal. Biogen Inc. and Capsigen Inc. announced they have entered into a strategic research collaboration to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised Prometheus Biosciences on the deal, while Davis Polk advised the representatives of the underwriters. Prometheus Biosciences,...
You must be a Standard 1 Year member to access this content.
